Abstract: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: The present disclosure provides an injectable and shearing-thinning microbeads gel including a first microgel and a second microgel. The first microgel has a first electric charge and includes a plurality of first gel microspheres. The second microgel has a second electric charge and includes a plurality of second gel microspheres. The first electric charge is opposite to the second electric charge, the average particle size of the first gel microspheres is equal to the average particle size of the second gel microspheres, each of the first gel microspheres includes an acrylic chitosan polymer, an acrylic silk polymer, or a combination thereof, and each of the second gel microspheres includes an acrylic gelatin polymer, an acrylic hyaluronic acid polymer, an acrylic alginate polymer, or a combination thereof.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS). The disclosure also provides a method of treating a metabolic disorder or disease by administering a therapeutically effective amount of the 3D-printed tablet to a subject in need thereof.

Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).

Abstract: A lutein microcapsule formulation and preparation method thereof, the formulation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxidant, and purified water. The preparation method comprises: dissolving the lutein crystals and the oil-soluble antioxidant in the water-soluble emulsifier to obtain an oil phase; adding the wall material, the water-soluble antioxidant, and the filler to the purified water to obtain a water phase; adding the oil phase to the water phase, grinding to obtain a particle size of the liquid emulsion of less than 100 nm, and granulating.

Abstract: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials.

Abstract: Compositions disclosed include pearlescent pigment, talc, boron nitride, and a lipid portion. The lipid portion includes a polydialkylsiloxane, a silicone wax, and a diester of a dicarboxylic acid and a fatty alcohol. The composition is substantially free of water. The composition is generally in the form of a pressed-powder. Methods of use are also disclosed.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS).

Abstract: The present invention provides compositions, methods and kits for treating skin, which combine administration of glucosamine hydrochloride and red light having a peak wavelength of about 600 nm to about 750 nm, near infrared light having a peak wavelength of about 750 nm to about 1000 nm, or both.

Abstract: Described herein are methods and compositions for—inter alia—lowering the specific gravity of urine and lowering the calcium oxalate risk index of in felines. In particular, diets and methods utilizing certain amounts and ratios of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.

Abstract: The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject.

Abstract: The present invention relates to topical composition comprising a cetyl phosphate surfactant mixture consisting essentially of mono- and/or dicetyl esters of phosphoric acid or salts thereof and cetylalcohol and inorganic phosphate and heavy metals and water, characterized in that the surfactant mixture contains no organochlorine impurities and has an inorganic phosphate content of less than 0.7 wt.-% and a heavy metal content of less than 12 ppm.